Home  /  Resource Library  /  Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?

Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?

Article discusses the use of surrogate endpoints in clinial trials versus more robust enpoints such as progression free survival.